Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101905 | 0.88 | PDE2A (0.31) | METCYP1A2CYP3A4TSHRHSD17B10 | |
| SCHEMBL22393761 | 0.85 | MET (0.30) | MET | |
| SCHEMBL22101706 | 0.77 | HTR1A (0.32) | ATML3MBTL1 | |
| SCHEMBL22101184 | 0.74 | CRHR1 (0.31) | — | |
| SCHEMBL22393766 | 0.74 | — | — | |
| SCHEMBL22393755 | 0.73 | P2RX7 (0.32) | — | |
| SCHEMBL22393707 | 0.73 | MAPK3 (0.31) | — | |
| SCHEMBL22393700 | 0.71 | ALDH1A1 (0.30) | — | |
| SCHEMBL22101707 | 0.70 | ALDH1A1 (0.32) | HSD17B10L3MBTL1 | |
| SCHEMBL22101906 | 0.70 | KDM4E (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | HCAR2 32/4885MET 132/4885CYP1A2 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.